ibandronic acid has been researched along with Carcinoma, Non-Small Cell Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bargagli, G; Conca, R; Cozzolino, A; Fiaschi, AI; Francini, E; Francini, F; Gotti, G; Martellucci, I; Miano, ST; Migali, C; Pascucci, A; Petrioli, R | 1 |
| Khuri, F; Saba, N | 1 |
1 review(s) available for ibandronic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
1 trial(s) available for ibandronic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Peptides; Treatment Outcome; Zoledronic Acid | 2011 |